Advisory - Isotechnika to Announce Interim Three Month Data From Phase 2b Kidney Transplant Trial

Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. will
announce interim three month data from its Phase 2b kidney
transplant trial for the Company's lead immunosuppressive drug,
ISA247 on Monday, May 7th at 6:00 a.m. ET/4:00 a.m. MT. The
management team will provide a review of the Phase 2b kidney
transplant trial via a live conference call on Monday, May 7th at
9:00 a.m. ET/7:00 a.m. MT. All interested parties will be able to
access the live event (audio only) through the Company's corporate
web site at www.isotechnika.com.

About Isotechnika

-----------------

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development
of novel immunosuppressive therapeutics that are safer than
currently available treatments. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead drug, ISA247, has successfully completed a
Phase 3 Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is currently being investigated in a combined
Phase 3 European/Canadian psoriasis trial and a Phase 2b North
American trial for the prevention of kidney graft rejection. One of
our partners, Lux Biosciences, has received permission from the Food
and Drug Administration to investigate ISA247 in three separate
pivotal Phase 2/Phase 3 trials for the treatment of non- infectious
uveitis and as a maintenance therapy in uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at www.isotechnika.com.

Partnerships

------------

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-(780)-909-4661,
Fax: +1-(780)-484-4105, E-mail: sgillis-paulgaard@isotechnika.com


	hier anmelden...